ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis

Zhong, Ping; Zeng, Hai; Huang, Miaochun; Fu, Wenbin*; Chen, Zhixia*广东省人民医院; 广州中医药大学
ENDOCRINE2022-3DOI: 10.1007/s12020-021-02945-1
23被引11阅读
引用收藏
分享

摘要

Purpose This meta-analysis aimed to assess the efficacy and safety of once-weekly semaglutide among adults with overweight or obesity. Methods We searched multiple electronic databases for randomized controlled trials that compared once-weekly semaglutide versus placebo in adults with overweight or obesity. The primary outcomes were the percentage change and absolute change in body weight. Secondary outcomes included achievement of categorical weight loss targets (at least 5, 10, 15, or 20%), cardiometabolic risk profiles, and health-related quality of life. Results This meta-analysis included a total of four trials with 3447 patients. Once-weekly semaglutide was superior to placebo in terms of the percentage change and absolute change in body weight. Compared with placebo, once-weekly semaglutide also led to significant increases in the proportions of achievement of categorical weight reduction targets. Moreover, once-weekly semaglutide induced superior reductions in waist circumference and body-mass index compared with placebo. Furthermore, the effect on improving other cardiometabolic risk factors and health-related quality of life was more pronounced for once-weekly semaglutide relative to placebo. Conclusion Among adults with overweight or obesity, once-weekly semaglutide could result in clinically meaningful weight loss, which was a promising therapy for treating overweight or obesity.

学科与关键词

关键词
Once-weekly semaglutideOverweightObesityWeight managementMeta-analysis
相关
加载中…
  • Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
    Xie, Zeyu; Yang, Sensen; Deng, Weishang; Li, Jinjian; Chen, Jisheng*Clinical Epidemiology, 2022, 14: 1463-1476.被引 8
  • Efficacy and safety of tirzepatide once weekly in Chinese participants with obesity or with overweight and weight-related comorbidities
    Zhao, L.; Cheng, Z.; Lu, Y.; Liu, M.; Chen, H.; Zhang, M.; Wang, R.; Wang, Y.; Yuan, Y.; Li, X.59th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Hamburg, GERMANY, 2023-10-02 To 2023-10-06.
  • Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis
    Li, Aihua; Su, Xiaorong; Hu, Shanshan*; Wang, Yong*Diabetes Research and Clinical Practice, 2023, 198: 110605.被引 6
查看全部 →

发表信息

论文状态
公开发表
期刊
ENDOCRINE
发表日期
2022-03
卷期
第 75 卷, 第 3 期
页码
718-724
DOI
10.1007/s12020-021-02945-1
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
Scientific Research project of Guangdong Provincial Administration of Traditional Chinese Medicine [2020KT1112]

作者

  • Z

    Zhong, Ping (第一作者)

    2 · guangzhou univ chinese med

  • Z

    Zeng, Hai

查看全部 5 位作者收起作者
  • H

    Huang, Miaochun

    guangdong prov hosp

  • F

    Fu, Wenbin (通讯)

    2 · guangzhou univ chinese med

  • C

    Chen, Zhixia (通讯)

    guangdong prov hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417